ASX:ACR Acrux (ACR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Acrux Stock (ASX:ACR) 30 days 90 days 365 days Advanced Chart Get Acrux alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume4,000 shsAverage VolumeN/AMarket CapitalizationA$12.47 millionP/E RatioN/ADividend Yield11.66%Price TargetN/AConsensus RatingN/A Company Overview Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia. Read More Receive ACR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrux and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACR Stock News HeadlinesAcrux Expands into Saudi Market with Servacure PartnershipJuly 30, 2025 | tipranks.comAcrux Limited Sees Change in Substantial ShareholdingJune 30, 2025 | tipranks.comSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split the entire U.S. market in two on or before Sept 30, causing a crisis "many times worse than 2008."August 30 at 2:00 AM | Altimetry (Ad)Top hiking boots for exploring trails while keeping your feet dryMay 20, 2025 | msn.comAcrux Limited Announces Registry Office RelocationApril 8, 2025 | tipranks.comAcrux Limited Announces Quotation of New Securities on ASXApril 3, 2025 | tipranks.comAcrux Secures $1.73 Million Advance on R&D Tax IncentiveApril 2, 2025 | tipranks.comSouth African group buys Cononish gold mineMarch 13, 2025 | uk.finance.yahoo.comSee More Headlines ACR Stock Analysis - Frequently Asked Questions How were Acrux's earnings last quarter? Acrux Limited (ASX:ACR) released its earnings results on Thursday, February, 21st. The company reported ($0.02) earnings per share (EPS) for the quarter. Acrux had a negative net margin of 113.93% and a negative trailing twelve-month return on equity of 130.13%. What other stocks do shareholders of Acrux own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acrux investors own include Altimmune (ALT), ANZ Group (ANZ), Lynas Rare Earths (LYC), MV Oil Trust (MVO), Organigram (OGI), BHP Group (BHP) and Beacon Roofing Supply (BECN). Company Calendar Last Earnings2/21/2019Today8/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryTrading Current SymbolASX:ACR CIKN/A Webwww.acrux.com.au Phone+61-3-83790100FaxN/AEmployees2,018Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$5.80 million Net Margins-113.93% Pretax MarginN/A Return on Equity-130.13% Return on Assets-48.18% Debt Debt-to-Equity Ratio113.06 Current Ratio1.61 Quick Ratio2.89 Sales & Book Value Annual SalesA$5.09 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.57 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares290,720,000Free FloatN/AMarket CapA$12.47 million OptionableNot Optionable Beta1.21 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (ASX:ACR) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrux Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.